Germany: Pandemic Pfizer, Biontech to Co-Develop Mrna-Based Vaccine to Fight Coronavirus
With an aim to protect patients detected with Covid-19 from all over the world, Pfizer and Biontech have entered into a letter of intent to create a potential vaccine for Coronavirus. Under the terms of the agreement, BNT162 – Biontech’s Covid-19 mrna vaccine programme will be fast-tracked and will enter clinical testing towards the end of April 2020.
Mainz/Germany – Pfizer and Biontech have recently announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mrna-based coronavirus vaccine aimed at preventing Covid-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
The collaboration aims to accelerate development of Biontech’s potential first-in-class Covid-19 mrna vaccine programme, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and Biontech entered in 2018 to develop mrna-based vaccines for prevention of influenza.
“We are proud that our ongoing, successful relationship with Biontech gives our companies the resiliency to mobilise our collective resources with extraordinary speed in the face of this worldwide challenge,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with Biontech’s mrna vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible.”
“This is a global pandemic, which requires a global effort. In joining forces with our partner Pfizer, we believe we can accelerate our effort to bring a Covid-19 vaccine to people around the world who need it,” said Ugur Sahin, Co-Founder and CEO of Biontech. The companies expect to utilise multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.
The companies will begin collaborating immediately. They will finalise details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialisation over the next few weeks. On March 13, 2020, Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat Covid-19.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46413143)